Switzerland· 67575001
Abecma Infusionsdispersion, von 260 bis 500 × 10e6 CAR-positiven lebensfähigen T-Zellen
A idecabtagene vicleucel product containing idecabtagenum vicleucelum 260-500 x 10⁶ car-positive viable t zellen, registered in Switzerland by Bristol-Myers Squibb SA and dispensed under Swissmedic category A. The same ATC class is registered in 10 of our 19 countries.
Checked against Swissmedic (Switzerland) on
Informational only — not a medical device.
Where it is registered
Idecabtagene vicleucel is registered in 10 of 19 countries.
Countries holding a registration under ATC L01XL07 (idecabtagene vicleucel), each read from that country’s own register.
- This record: Switzerland, from Swissmedic (Switzerland)
- 8 of them publish a price we can compare per daily dose
Idecabtagene vicleucel · ATC L01XL07
10 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Netherlands
- Polandprice
- Switzerlandprice
- United Statesprice
The record
At a glance
Swissmedic (Switzerland)- Active substance
- idecabtagenum vicleucelum 260-500 x 10⁶ CAR-positive viable T Zellen
- Manufacturer
- Bristol-Myers Squibb SA
- Country
- Switzerland (CH)
- ATC code
- L01XL07
- ATC class
- Idecabtagene vicleucel
- Swissmedic category
- A
- Reimbursed
- No
- Source register
- Swissmedic (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Idecabtagene vicleucel in 11 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesAbecmaCelgene Corporation
- CzechiaABECMABristol-Myers Squibb Pharma EEIG, Dublin
- SpainABECMA 260-500 x 10e6 CELULAS DISPERSION PARA PERFUSIONBristol-Myers Squibb Pharma Eeig
- FinlandAbecmaBristol-Myers Squibb Pharma EEIG
- FranceABECMA 260 - 500 x 1 000 000 cellules, dispersion pour perfusionBRISTOL-MYERS SQUIBB PHARMA (IRLANDE)
- BelgiumAbecma 260-500 x 10*6 cellsBristol-Myers Squibb Pharma
- IcelandAbecmaBristol-Myers Squibb Pharma EEIG*
- Japanイデカブタゲン ビクルユーセルブリストル・マイヤーズ スクイブ
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Abecma
- Liechtenstein · Abecma
- Norway · Abecma
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c112efbc-759d-4f39-99e2-1acf4ca1d95b GET /v1/drugs/c112efbc-759d-4f39-99e2-1acf4ca1d95b?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"source": "swissmedic_auth",
"heilmittelcode": "Transplantat: Gentherapieprodukt"
}See everything about idecabtagene vicleucel.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.